125459

The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459

: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA. 125459

: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells. The guideline, officially titled , provides a framework

: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : 125459

: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy.